FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
Nov 16, 2023 · FDA approves KEYTRUDA, an anti-PD-1 therapy, in combination with chemotherapy for the first-line treatment of HER2-negative gastric or GEJ adenocarcinoma. The approval is based on data from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) …
May 5, 2021 · The FDA has approved KEYTRUDA, an anti-PD-1 therapy, in combination with trastuzumab and chemotherapy for the first-line treatment of HER2-positive gastric or gastroesophageal junction adenocarcinoma. The approval is based on a Phase 3 trial that showed a significant improvement in objective response rate and durability of response.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
Jun 17, 2024 · The FDA has approved KEYTRUDA, an anti-PD-1 therapy, in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma. The approval is based on data from the Phase 3 KEYNOTE-868 trial, which showed a 40% reduction in disease progression or death.
FDA approves neoadjuvant/ adjuvant pembrolizumab for …
Oct 16, 2023 · Pembrolizumab (Keytruda) is approved for neoadjuvant and adjuvant treatment of resectable non-small cell lung cancer (NSCLC) based on the KEYNOTE-671 trial. The trial showed improved overall...
Adjuvant Keytruda Improves Kidney Cancer Survival - NCI
May 21, 2024 · A clinical trial shows that pembrolizumab, an immunotherapy drug, can reduce the risk of death by 40% in people with high-risk kidney cancer after surgery. The FDA approved pembrolizumab as an adjuvant treatment in 2021, but its use is not yet widespread.
FDA approves pembrolizumab combination for the first-line …
Pembrolizumab (Keytruda) is a PD-1 inhibitor that can treat persistent, recurrent or metastatic cervical cancer with PD-L1 expression. The FDA approval was based on a randomized trial...
FDA approves pembrolizumab as adjuvant treatment for non …
Jan 26, 2023 · Keytruda (pembrolizumab) is now indicated for stage IB, II, or IIIA non-small cell lung cancer patients who undergo surgery and platinum-based chemotherapy. The approval is based on a trial...
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab …
Dec 15, 2023 · PADCEV is an antibody-drug conjugate (ADC) and pembrolizumab is a PD-1 inhibitor. The combination is the first to offer an alternative to platinum-containing chemotherapy and nearly doubled median overall survival compared to chemotherapy in a Phase 3 trial.
Changes to Treatment for HER2-Positive Gastric Cancer - NCI
Nov 17, 2023 · Pembrolizumab (Keytruda) can now be used with trastuzumab and chemotherapy for people with advanced HER2-positive stomach or gastroesophageal junction cancer whose tumors have high PD-L1 levels. The FDA also approved pembrolizumab plus chemotherapy for HER2-negative gastric and GEJ cancer.
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of ... - Merck
Jul 27, 2021 · KEYTRUDA is the first immunotherapy regimen for high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant and adjuvant treatment. The approval is based on the Phase 3 KEYNOTE-522 trial that showed a 37% reduction in the risk of disease progression.
- Some results have been removed